Oxford BioMedica Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies

Oxford BioMedica Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies PR Newswire OXFORD, England, August 8, 2012 OXFORD, England, August 8, 2012 /PRNewswire/ -- ®-- Treatment of final RetinoStat patient cohort underway -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, and its partner Sanofi (EURONEXT: SAN and NYSE: SNY) today announce a positive interim review of ®the RetinoStat Phase I study in neovascular "wet" age-related macular degeneration (AMD) and the StarGen™ Phase I/IIa study in Stargardt disease by the Data Safety Monitoring Board (DSMB); an independent panel of specialists ®in the fields of ophthalmology, virology and vectorology. RetinoStat and StarGen™ were designed and developed by Oxford BioMedica using the ®Company's proprietary LentiVector gene delivery technology. ®DSMB highlights of ongoing RetinoStat Phase I study Nine patients treated to date (n=3 at each of dose levels 1, 2 and 3) ®No serious adverse events related to RetinoStat or its method of administration Long-term safety profile now up to 18 months post-treatment (dose level 1) Successful retinal transduction, as shown by substantial increase in expression and secretion of endostatin and angiostatin proteins measured in the anterior chamber of the ®eye following a single administration of RetinoStat .